Managed entry agreements and high cost medicines (European perspective)

This chapter provides an overview on Managed Entry Agreements (MEA). Managed Entry Agreements are contracts between the industry and payers under which a drug gets access to the market. The first two sessions illustrate the rationale and taxonomy of MEA, that could be designed as financial-based or outcome-based agreement. The third one describes how these agreements have been implemented in Europe. The fourth section illustrates the results of the few studies that have investigated the impact of MEA and some thoughts on future perspectives for these contracts.